CHOSA — Chosa Oncology AB Share Price
0.000.00%
Last trade - 00:00- SEK64.87m
- SEK56.10m
- SEK0.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.73 | ||
| Price to Tang. Book | 8.64 | ||
| Price to Free Cashflow | 3.97 | ||
| Price to Sales | 888.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -135.04% | ||
| Return on Equity | -178.66% | ||
| Operating Margin | -32208.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 5.98 | 6.01 | 10.19 | 4.08 | 0.07 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chosa Oncology AB, formerly RhoVac AB, is a Sweden-based biotechnology company. The Company specializes on research and development of immunotherapeutic drugs. The Company's business focus is found in the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is an important part of the operation where the body's own immune system is used to fight and eliminate cancer cells. The Company's drug candidate is used in combination with surgery or radiotherapy. Its products are iCIP, which is combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity; LiPlaCis is a liposomal formulation of cisplatin enabling direct delivery of this known agent to tumor sites; and DRP is a multigene mRNA-based Drug-specific Response Predictor built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types.
Directors
- Gunnar Gardemyr CHM (62)
- Anders Mansson CEO (52)
- Henrik Stage CFO (62)
- Anders Ljungqvist COO
- Cristina Glad DRC (67)
- Lars Hedbys DRC
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 25th, 2015
- Public Since
- March 9th, 2016
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 64,873,913
- Address
- Medicon Village, Scheeletorget 1, LUND, 223 81
- Web
- https://www.chosaoncology.com/
- Phone
- +46 40832365
- Auditors
- Deloitte AB
Upcoming Events for CHOSA
Similar to CHOSA
Abera Bioscience AB
AktieTorget Stock Exchange
Aptahem AB
AktieTorget Stock Exchange
Arcede Pharma AB
AktieTorget Stock Exchange
Carbiotix AB (publ)
AktieTorget Stock Exchange
Curasight A/S
AktieTorget Stock Exchange
FAQ
What is the Chosa Oncology AB share price?
As of Today at 19:05 UTC, shares in Chosa Oncology AB are trading at SEK1.00. This share price information is delayed by 15 minutes.
How has the Chosa Oncology AB share price performed this year?
Shares in Chosa Oncology AB last closed at SEK1.00 and the price had moved by -32.98% over the past 365 days. In terms of relative price strength the Chosa Oncology AB share price has underperformed the FTSE Global All Cap Index by -38.18% over the past year.
What are the analyst and broker recommendations for Chosa Oncology AB?
There is no consensus recommendation for this security.
What is the Chosa Oncology AB dividend yield?
Chosa Oncology AB does not currently pay a dividend.
Does Chosa Oncology AB pay a dividend?
Chosa Oncology AB does not currently pay a dividend.
When does Chosa Oncology AB next pay dividends?
Chosa Oncology AB does not currently pay a dividend.
How do I buy Chosa Oncology AB shares?
To buy shares in Chosa Oncology AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chosa Oncology AB?
As of the previous close price of SEK1.00, shares in Chosa Oncology AB had a market capitalisation of SEK64.87m.
Where are Chosa Oncology AB shares listed?
Here are the trading details for Chosa Oncology AB:
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: CHOSA
What kind of share is Chosa Oncology AB?
Based on an overall assessment of its quality, value and momentum Chosa Oncology AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chosa Oncology AB share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Chosa Oncology AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chosa Oncology AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +24.07%.
As of the last closing price of SEK1.00, shares in Chosa Oncology AB were trading +33.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chosa Oncology AB PE Ratio?
The Chosa Oncology AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK1.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chosa Oncology AB?
Chosa Oncology AB's management team is headed by:
- Gunnar Gardemyr - CHM
- Anders Mansson - CEO
- Henrik Stage - CFO
- Anders Ljungqvist - COO
- Cristina Glad - DRC
- Lars Hedbys - DRC